NANTKWEST INC. DL-,0001 Forum: Community User: Ibt2

Hört sich so an als ob viele Firmen ihr Covid-19 Programm bezahlt bekommen werden. Also wird das, egal wie es ausgeht, kein ganz großes finanzielles Risiko.

US-Präsident Donald Trump kündigt ein Großprojekt zur schnellen Entwicklung eines Impfstoffes an. Der landläufig als "Operation Warp Speed" bekannte Vorstoß soll Chefsache werden. "Was immer menschenmöglich ist, wir werden es haben", sagt Trump. Insider sprachen von einer Zusammenarbeit zwischen Pharmafirmen, Regierungsbehörden und dem US-Militär, um bis Ende 2020 Millionen von Impfdosen zur Verfügung zu stellen. Experten gehen zurzeit davon aus, dass klinische Studien zur Gewährleistung der Sicherheit und Wirksamkeit eines Impfstoffs mindestens zwölf bis 18 Monate in Anspruch nehmen könnten.

Jo, 4$ mal wieder durchbohrt, auch wenn es wahrscheinlich nicht der Tagesendstand sein wird, gutes Zeichen.

Sehr stabil heute 👍

Ich frage mich, bei all den Investitionen und der Größe die Nantkwest die letzten Jahre angenommen hat, wie dieses Unternehmen immer noch, mit nur 365Millionen Euro bewertet ist...

Patrick Soon-Shiong, the billionaire biomedical entrepreneur and owner of the Los Angeles Times, has moved on two fronts to fight the Covid-19 pandemic in recent weeks. Soon-Shiong has acquired a Los Angeles hospital out of bankruptcy and plans to establish a coronavirus research facility on its campus. And he has pivoted his two immunotherapy companies to develop potential therapies and vaccines to fight the virus. Soon-Shiong’s bid to buy the shuttered St. Vincent Medical Center in Westlake from bankrupt Verity Health System for $135 million was approved April 10 by U.S. Bankruptcy Court Judge Ernest Robles. But the deal came with some controversy. Soon-Shiong’s bid had come under fire from state Attorney General Xavier Becerra because a company under Soon-Shiong’s control — Integrity Healthcare — was also the management company for Verity Health and one of its secured creditors in the bankruptcy proceeding. Soon-Shiong agreed to acquire the hospital personally instead of having his family foundation buy it, and Becerra withdrew his objections to the sale. In addition, Soon-Shiong agreed to honor the three-month lease agreement reached in March by the state with Verity to turn the hospital — which shut down in January — into a facility to treat Covid-19 patients. The hospital reopened under the lease terms on April 13. Soon-Shiong also announced he would establish a coronavirus research facility at the hospital. Also fighting the current coronavirus contagion, two of Soon-Shiong’s biomedical companies — publicly traded NantKwest Inc. and private company ImmunityBio Inc. — jointly announced April 14 that they were in discussions with the Food and Drug Administration about developing immunotherapy-based treatments and vaccines to combat Covid-19. The announcement said the two companies are combining their research and development capabilities for this effort. It also said they have applied for Investigational New Drug applications with the FDA for one vaccine drug against the coronavirus and three therapeutic drugs to treat patients with various stages of the disease. Clinical trials for these drugs could begin as soon as this quarter, the announcement said. “We’re in a race against time, but I am confident that, as a result of the incredible hard work the NantKwest, ImmunityBio, and the global scientific communities are undertaking, we will find effective therapeutics and vaccines against this coronavirus,” Soon-Shiong said in the announcement. He noted that ImmunityBio had experience developing a vaccine for the H1N1 flu virus, which caused a pandemic in 2009, and that it is applying a modified version of that vaccine drug platform to fight the coronavirus that causes Covid-19. NantKwest and ImmunityBio are both part of Soon-Shiong’s NantWorks family of companies. NantKwest is headquartered in Culver City, while ImmunityBio is based in El Segundo. Soon-Shiong is chief executive of both companies. https://labusinessjournal.com/news/2020/apr/20/soon-shiong-sets-sights-coronavirus/

NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference by Jen Hodson | Apr 29, 2020 | Press Releases EL SEGUNDO, Calif., April 29, 2020 – NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET. A live audio webcast of the conference presentation will be available on the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com.  An archived replay will be available on the websites for approximately 30 days. Dr. Soon-Shiong will present a clinical pipeline update with registrational strategies for NantKwest’s off-the-shelf natural killer cell-based therapeutics in combination with ImmunityBio’s N-803 Interleukin 15 (IL-15) ‘superagonist’ cytokine. He will also provide an update on the companies’ COVID-19 therapeutic and vaccine candidates.

Hoffentlich haut Nantkwest bald die Bombe raus oder Dr. Patrick Soon Shiong deutet schon mal was an auf Twi.tter an 😊

Ob da wohl jemand umgeschichtet hat... Nanthealth +26% Nantkwest -9% ....

Oder Heute schon :)

Die 4$ Marke wird nicht lange halten, in ein paar Wochen wird sie Geschichte sein.

Staeret

T.witter

Twitter, 17.04.2020 Dr. Pat Soon-Shiong @DrPatSoonShiong 17. Apr. 7 days later, @NantKwest @ImmunityBio making progress in culturing #MSC cells from bone marrow for our work against #COVID19

Ist aber sehr behäbig die alte Dame, morgens bis frühnachmittags ist sie gut drauf, danach verliert sie meist ihre Kraft. Gab schon lange keine News zur eigentlichen Pipeline mehr...!?

Fängt an Spaß zu machen 😊